Tesamorelin
FDA APPROVEDGHRH analog | Visceral fat reduction
Overview
What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH), FDA-approved for HIV-associated lipodystrophy. It selectively reduces visceral fat while preserving subcutaneous fat, which makes it unique among growth hormone therapies.
Key benefits
FDA-approved formulation, selective action on visceral fat, proven clinical efficacy and standardized dosing.
Mechanism of action
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation.
Quick start guide
What to expect
- Week 1-2: IGF-1 begins to rise, possible mild water retention or joint discomfort.
- Week 4-6: early metabolic changes, slight improvement in energy and sleep quality.
- Week 8-12: visible visceral fat reduction begins; waist circumference may decrease.
- Week 12-26: peak effects with significant body composition improvements.
Side effects & safety
- Monitor blood glucose regularly: a 3.3-fold increased diabetes risk has been documented.
- IGF-1 levels should be checked monthly: 47% exceed the normal range at 26 weeks.
- Contraindicated in active cancer or pituitary disorders.
- Common side effects include injection-site reactions (17%) and joint pain (13%).
- Allergic reaction: rash, itching or swelling.
- Persistent increase in thirst, urination or blood sugar levels.
- Swelling, numbness or tingling in the hands (possible carpal tunnel syndrome).
- If you are pregnant, breastfeeding or planning a pregnancy.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a growth hormone releasing hormone (GHRH) analog, FDA-approved for HIV-associated lipodystrophy. It selectively reduces visceral fat.
What is Tesamorelin used for?
It is used to reduce visceral fat and stimulate natural growth hormone production.
How does Tesamorelin work?
It binds to the GHRH receptor and stimulates the pulsatile, physiological release of growth hormone.
How long does Tesamorelin take to work?
IGF-1 usually rises around 2 weeks, visible fat loss appears in 4-8 weeks and peak effects between 12 and 26 weeks.
What is the usual Tesamorelin dose?
The approved dose is 1.4 mg per day; up to 2 mg per day has been used in research. The schedule is set by a professional.
How is Tesamorelin administered?
By daily subcutaneous injection, preferably at night to match the natural GH rhythm.
How is Tesamorelin stored?
The powder refrigerated and, reconstituted, at room temperature (do not refrigerate after mixing, per the leaflet). See the storage guide.
What are the side effects of Tesamorelin?
Injection-site reactions and joint pain; it is advisable to monitor glucose and IGF-1 levels.
Which peptides is Tesamorelin combined with?
It is sometimes paired with other GH secretagogues; any combination should be assessed by a professional.
Is Tesamorelin approved?
Yes, it is FDA-approved for HIV-associated lipodystrophy.
What is the difference between Tesamorelin, Sermorelin and CJC-1295?
All act on the GHRH axis, but tesamorelin stands out for its selective action on visceral fat.
Research areas
- Visceral fat reduction
- Growth hormone stimulation
- Metabolic health
- Body composition
- IGF-1 levels
Related peptides
- CJC-1295 — GHRH analog for growth hormone.
- Sermorelin — GHRH 1-29 analog, also of the GH axis.
- Semaglutide — GLP-1 receptor agonist for weight and diabetes.
Related articles
Related topics
- Tesamorelin for visceral fat
- Tesamorelin dose
- Tesamorelin side effects
- Tesamorelin and growth hormone
- Tesamorelin Egrifta
- Tesamorelin and body composition
Summary
What it is: GHRH analog FDA-approved for HIV-associated lipodystrophy.
How it is researched: Daily subcutaneous injection; 1.4 to 2 mg.
Key features: Selectively reduces visceral fat and stimulates natural GH.
Related peptides: CJC-1295, Sermorelin and Semaglutide.